Expression of human CD1d molecules protects target cells from NK cell-mediated cytolysis

Journal of Immunology

Volumn 172, Issue 12, 2004, Pages 7297-7305

  Campos Martín, Yolanda ^a   Del Moral, Manuel Gómez ^a   Gozalbo López, Beatriz ^a   Suela, Javier ^a   Martínez Naves, Eduardo ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; BETA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CERAMIDE; COMPLEMENTARY DNA; IMMUNOGLOBULIN F(AB')2 FRAGMENT; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; RNA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CYTOLYSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TARGET CELL;

EID: 2942616772     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.12.7297     Document Type: Article

References (34)

1. Moretta, A., C. Bottino, M. Vitale, D. Pende, C. Cantoni, M. C. Mingari, R. Biassoni, and L. Moretta. 2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis, Annu. Rev. Immunol. 19:197.
2. Karre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 319:675.
3. Lanier, L. L. 1998. NK cell receptors. Annu. Rev. Immunol. 16:359.
4. Lopez-Botet, M., M. Llano, F. Navarro, and T. Bellon. 2000. NK cell recognition of non-classical HLA class I molecules. Semin. Immunol. 12:109.
5. Braud, V. M., D. S. Allan, C. A. O'Callaghan, K. Soderstrom, A. D'Andrea, G. S. Ogg, S. Lazetic, N. T. Young, J. I. Bell, J. H. Phillips, et al. 1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391:795.
6. Vance, R. E., J. R. Kraft, J. D. Altman, P. E. Jensen, and D. H. Raulet. 1998. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). J. Exp. Med. 188:1841.
7. Chiang, E. Y., M. Henson, and I. Stroynowski. 2002. The nonclassical major histocompatibility complex molecule Qa-2 protects tumor cells from NK cell- and lymphokine-activated killer cell-mediated cytolysis. J. Immunol. 168:2200.
8. Hughes, A. L., M. Yeager, A. E. Ten Elshof, and M. J. Chorney. 1999. A new taxonomy of mammalian MHC class I molecules. Immunol. Today 20:22.
9. Porcelli, S. A., and R. L. Modlin. 1999. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu. Rev. Immunol. 17:297.
10. Porcelli, S. A. 1995, The CD1 family: a third lineage of antigen-presenting molecules. Adv. Immunol. 59:1.
11. Zeng, Z., A. R. Castano, B. W. Segelke, E. A. Stura, P. A. Peterson, and I. A. Wilson. 1997. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 277:339.
12. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science 278:1626.
13. Kronenberg, M., and L. Gapin. 2002. The unconventional lifestyle of NKT cells, Nat. Rev. Immunol. 2:557.
14. Chang, C. S., L. Brossay, M. Kronenberg, and K. P. Kane. 1999. The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis. J. Exp. Med. 189:483.
15. Carbone, E., G. Terrazzano, A. Melian, D. Zanzi, L. Moretta, S. Porcelli, K. Karre, and S. Zappacosta. 2000. Inhibition of human NK cell-mediated killing by CD1 molecules. J. Immunol. 164:6130.
16. Shimizu, Y., and R. DeMars. 1989. Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. J. Immunol. 142:3320.
17. Edwards, P. A., C. M. Smith, A. M. Neville, and M. J. O'Hare. 1982. A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur. J. Immunol. 12:641.
18. - T cells. J. Exp. Med. 186:109.
19. 2-microglobulin. J. Biol. Chem. 274:9289.
20. Martinez-Naves, E., L. D. Barber, J. A. Madrigal, C. M. Vullo, C. Clayberger, S. C. Lyu, R. C. Williams, C. Gorodezky, T. Markow, M. L. Petzl-Erler, and P. Parham, 1997. Interactions of HLA-B*4801 with peptide and CD8. Tissue Antigens 50:258.
21. Oteo, M., P. Arribas, F. Setien, J. F. Parra, I. Mirones, D. M. Gomez, and E. Martinez-Naves. 2001. Structural characterization of two CD1A allelic variants. Hum. Immunol. 62:1137.
22. Robertson, M. J., K. J. Cochran, C. Cameron, J. M. Le, R. Tantravahi, and J. Ritz, 1996. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 24:406.
23. Biesinger, B., I. Muller-Fleckenstein, B. Simmer, G. Lang, S. Wittmann, E. Platzer, R. C. Desrosiers, and B. Fleckenstein. 1992. Stable growth transformation of human T lymphocytes by herpesvirus saimiri. Proc. Natl. Acad. Sci. USA 89:3116.
24. Gumperz, J. E., S. Miyake, T. Yamamura, and M. B. Brenner. 2002. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195:625.
25. Brossay, L., M. Chioda, N. Burdin, Y. Koezuka, G. Casorati, P. Dellabona, and M. Kronenberg. 1998. CD1d-mediated recognition of an α -galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188:1521.
26. Dascher, C. C., and M. B. Brenner. 2003. Evolutionary constraints on CD1 structure: insights from comparative genomic analysis. Trends Immunol. 24:412.
27. Zemmour, J., A. M. Little, D. J. Schendel, and P. Parham. 1992. The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J. Immunol. 148:1941.
28. Storkus, W. J., M. Wei, P. Cresswell, and J. R. Dawson. 1996. Class I-like CD1A-C do not protect target cells from NK-mediated cytolysis. Cell. Immunol. 167:154.
29. Joyce, S., A. S. Woods, J., W. Yewdell, J. R. Bennink, A. D. De Silva, A. Boesteanu, S. P. Balk, R. J. Cotter, and R. R. Brutkiewicz. 1998. Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science 279:1541.
30. De Silva, A. D., J. J. Park, N. Matsuki, A. K. Stanic, R. R. Brutkiewicz, M. E. Medof, and S. Joyce. 2002. Lipid protein interactions: the assembly of cD1d1 with cellular phospholipids occurs in the endoplasmic reticulum. J. Immunol. 168:723.
31. Gumperz, J. E., C. Roy, A. Makowska, D. Lum, M. Sugita, T. Podrebarac, Y. Koezuka, S. A. Porcelli, S. Cardell, M. B. Brenner, and S. M. Behar. 2000. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12:211.
32. + T cell lymphoma by natural killer T (NKT) cells. Proc. Natl. Acad. Sci. USA 99:8197.
33. Rauch, J., J. Gumperz, C. Robinson, M. Skold, C. Roy, D. C. Young, M. Lafleur, D. B. Moody, M. B. Brenner, C. E. Costello, and S. M. Behar. 2003. Structural features of the acyl chain determine self-phospholipid antigen recognition by a CDld-restricted invariant NKT (iNKT) cell. J. Biol. Chem. 278:47508.
34. Ortaldo, J. R., H. A. Young, R. T. Winkler-Pickett, E. W. Bere, Jr., W. J. Murphy, and R. H. Wiltrout. 2004. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides 1. J. Immunol. 172:943.